Replies to post #286036 on Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM Scientist Dr.Michael.Gray speaking today: CHI I-O Conference/SanFran

Feb20-22 2017: “CHI’s 5th Translational Models in Oncology & Immuno-Oncology”, SanFran
“Models & Approaches to Bring Combination Therapies to the Clinic”
Part of the 24th Intl. Molecular Medicine Tri-Conference
http://www.triconference.com/Pre-Clinical-Oncology-Models
CHI = Cambridge Healthtech Institute http://www.healthtech.com
Track: TUMOR MODELS FOR CANCER IMMUNOTHERAPY
2-21-17 11:15-11:45am: Michael Gray (Sr.Res.Sci.), Peregrine Pharmaceuticals - “Case Study: Blockade of PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
SUMMARY: Phosphatidylserine (PS) exposure in tumors induces non-inflammatory signals which contribute to an immunosuppressive environment. Antibody blockade of PS activates immune responses by promoting M1 macrophages, maturation of dendritic cells and inducing adaptive T-cell responses. PS targeting antibodies enhance the anti-tumor activity of checkpoint antibodies in preclinical tumor models.
- - - - -
DR. MICHAEL GRAY (Principal Scientist, Peregrine 12-2014) - Prev: Quanticel Pharm, OSI; PhD/U-Pitt, Post-Doc/MDA https://www.linkedin.com/in/michael-gray-18447328
- - - - - -
BAVI MOA 5-11-16 Breast Cancer Res. article, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC” http://tinyurl.com/zxu882y
Lead author: Michael Gray; Senior author: Bruce Freimark; Co-author: Christopher C. W. Hughes(U-Cal/Irvine)
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”

[north40000]

I gather, CJG, that PPHM is not presenting an abstract/results at this site, ASCO/SITC in Orlando, in a few days:

http://abstracts.asco.org/194/AbstView_194_178747.html

http://ih.advfn.com/p.php?pid=nmona&article=73800520

[cjgaddy]

Reminder/Mar1: On/Feb12, AACR’17 revealed a 2nd(new) joint PPHM+MemSloan poster (study) that the Wolchok Lab will present on 4-3-17, “Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model”. We only know the TITLE at this point. On Wed. 3-1-17 4:30pmET, AACR’17 will publish the Abstract Summaries at http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&DetailItemID=539 . This has obviously be known for some time by Mem.Sloan & Peregrine – the deadline for “regular abstracts” was Nov. 17th, and for “late breakers” was Jan. 12th.

= = = = = = = = = = = = =WHAT WE DO KNOW:
The New PPHM+Mem.Sloan/Wolchok PS-Targeting Study was revealed via AACR’17 Abstracts pub. 2-12-17 at http://www.abstractsonline.com/pp8/#!/4292 . I’m learning more about this cancer immunotherapy approach called “Adoptive Cell Transfer (ACT)” that The Wolchok Lab & Peregrine are working on. It’s a bigger deal than I thought...

THIS IS THE NEW MSK/PPHM STUDY REVEALED BY THE AACR’17 ABSTRACTS: (see http://tinyurl.com/z47hb2s ):
#2: AACR’17(4-3-17) http://tinyurl.com/jxfm3hb
4-3-17/8am #1651 - Session: TUMOR MICROENVIRONMENT & CHECKPOINTS
“Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model”
=> Daniel Hirschhorn-Cymerman 1, Sara Sara Schad 1, Sadna Budhu 1, Zhong Hong 1, Xia Yang 1, Jeff Hutchins 2, Bruce Freimark 2, Michael Gray 2, Jedd Wolchok 1, Taha Merghoub [Memorial Sloan Kettering]
1=Memorial Sloan Kettering CC, NYC [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ]
2=Peregrine Pharmaceuticals
***FULL ABSTRACTS TO PUB. AT AACR.COM 3-1-17.

“Adoptive Cell Transfer (ACT)” is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system, with the goal of improving immune functionality and characteristics. In cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient.

**From 3-2014 Immunotherapy article: “Cancer immunotherapy, particularly adoptive cell transfer (ACT), has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to std. Therapies” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372895

**Through the support from SEAN PARKER, Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) formed an Immunology Research Dream Team dedicated to cancer immunology: “Immunologic Checkpoint Blockade & Adoptive Cell Transfer in Cancer Therapy.” The Immunotherapy Dream Team is focused on 2 approaches for this translational cancer research project, which will unite laboratory & clinical efforts towards the immunological treatment, control, and prevention of cancer.
The 1st is investigating blockades (by inhibitory molecules called “checkpoints”) of T lymphocytes’ inhibitory receptors, which block immune responses; and the use of antibodies to remove the checkpoints, once again allowing white blood cells called T lymphocytes to kill the cancer cells.
Second, the Immunotherapy Dream Team is pursuing multiple Adoptive Cell Transfer (ACT) approaches, which increase immunity.”
DREAM TEAM LEADERSHIP: 10 scientists, incl. MSKCC’s Jedd D. Wolchok & Michel Sadelain.
http://parker.org/initiatives/immunotherapy

**12-12-2012: MSK Researchers Jedd Wolchok & Michel Sadelain Appointed to “Stand Up To Cancer” Immunology “Dream Team”...
TWO APPROACHES TO ATTACKING CANCER:
The Immunology Dream Team will pursue 2 research techniques.
The 1st, being led by Dr. Wolchok, involves studying how a type of white blood cell called a T lymphocyte, or T cell, can kill cancer cells. Sometimes, the natural function of the T lymphocyte is blocked or not activated enough to attack cancer cells, allowing the cancer to grow ["Immunologic Checkpoint Blockade"]. Part of the Dream Team’s focus will be to investigate ways to ensure that the T lymphocytes work properly in recognizing and killing cancer cells.
The 2nd immunotherapy approach, known as Adoptive Cell Transfer (ACT), involves removing some of a patient’s T cells, enhancing their cancer-fighting abilities and growing them in the laboratory, and then infusing the enhanced cells back into the patient. This can provide a patient with an army of immune cells specifically programmed to fight against cancer. This part of the Dream Team’s research, led by Dr. Sadelain, will investigate several ways to use ACT as a cancer therapy.
https://www.mskcc.org/blog/msk-researchers-appointed-stand-immunology-dream-team

= = = = = = = = = = = = =
Apr1-5: AACR 2017, WashDC http://tinyurl.com/jxfm3hb (Abstract Summaries pub. 3-1-17)
...MSKCC+PPHM: 4-2-17/1pm #574, “PSTargeting+RAD+AntiPD1 Promotes Anti-Tumor Activity, Melanoma”
...MSKCC+PPHM: 4-3-17/8am #1651, “PSTargeting+Adoptive TCell Transfer Elims. Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=NEW MSK STUDY
...PPHM: 4-4-17/8am #3652, “PSTargeting+LAG3+AntiPD1 Significantly Enhances Anti-Tumor Activity, Triple- MBC”
...IMMUNOVACCINE+PPHM: 4-4-17/8am #3657, ”PSTargeting Enhances Anti-Tumor Activity of a Tumor Vaccine(DepoVax), HPV-Induced Tumor”

MOST INTERESTING: Mem. Sloan’s Dr. Jedd. Wolchok is co-author of 5 AACR’17 Posters. 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. http://www.abstractsonline.com/pp8/#!/4292
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma”
2. 4-3-17 #1651 “Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model”
NON-PEREGRINE:
3.(MSK ONLY): 4-2-17 #874 “Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy”
4.(MSK & Genocea Bio. http://www.genocea.com GNCA/$130mm MktCap) 4-2-17 #632 “Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a NSCLC patient”
5.(MSK & Cedars-Sinai/LA) 34-4-17 #4705 “CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM)”
.
.
SITC’16 PPHM/Mem.Sloan Poster – same as AACR’17 4-2-17 #574…

Preclin. Anti-PS work w/collab’s MemSloan, Duke, MDA, Rutgers, Wistar, ImmunoVaccine…
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128740654

[cjgaddy]

Which will break 1st? What order the rest?

* The PS+ Exosomes Program: esp. given UTSW’s Dr. Alan Schroit’s reputation; initial POC done/advancing via partnership. See: http://tinyurl.com/zbwr7cc

* Sunrise Biomarkers: #1=B2GPI, #2=Complement & IL-10 Pathways(12-7-26/IASLC delayed, “not done”, after prelim. abstract said, “Pts=193, within the 1st subgroup of N=104, a 2nd subgroup isolated: MOS 5.9=>12.5mos.”, #3=???. See http://tinyurl.com/jbv3ms5

* The MSK/Wolchok collab: incl. revelation by the new(2nd) AACR’17 MSK abstract stating, “PPHM’s PS-Targeting + Adoptive Tcell Transfer(ACT) Eliminates Advanced Tumors without Off-Target Toxicities”. Plus, Dr. Wolchok co-author of 5 AACR’17 Posters: 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. See: http://tinyurl.com/z47hb2s

* The Rutgers/R.Birge collab: ex: “PS Sensing by TAM Receptors (Tyro3, Axl, Mertk) Regulates AKT-dep. Chemoresistance & PD-L1 Expression”) - 2/9/17/AACR. See: http://tinyurl.com/h4gdke3

* The Duke/H.Lyerly collab: ex: “AntiPS + antiPD-L1 leads to greater anti-tumor responses in TNBC” - latest is 10-22-16/AACR I-O Conf. – see: http://tinyurl.com/zzryfok

* The MDA/JB.Fleming collab: ex: “PreClin. Eval of DNAtrix’s DNX2401+FhuBAVI(1N11) for Pancreatic Cancer - significantly inhibited tumor growth; further enhanced its anticancer activity; warrants further clinical evaluation...”, 1-30-17 AACR(Mol.Cancer). See: http://tinyurl.com/hov4hfb

* The ImmunoVaccine Inc. collab: “PS-Targeting Enhances Anti-Tumor Activity of DepoVax Tumor Vaccine” - per AACR’17 4-4-17 poster. See: http://tinyurl.com/jxfm3hb

* The AZN & NCCN clinical collabs: Sunrise Biomarkers adjusted?

* Continuing Avid expansion/revs-growth.

MORE ON PRE-CLIN. COLLABS HERE: http://tinyurl.com/gwa2gkn
.
.
.
= = = = = = = = = = = KNOWN UPCOMING EVENTS:
Feb27-Mar2/Avid Booth #816: BioProcess Intl. West, SanFran https://lifesciences.knect365.com/bpi-west PR: http://tinyurl.com/zbflrcf

~Mar8: FY'17Q3 (qe 1-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

Mar14/Avid: Repligen Corp's "Driving Bioprocessing Efficiency Seminar", Carlsbad http://www.repligen.com/sandiego2017 PR: http://tinyurl.com/zbflrcf
...2:45pm: Dr. David Briggs (Avid Scientist), "Case study: Positive Impact of Pre-packed Columns in a Multi-product Mfg. Facility"

Apr1-5: AACR 2017, WashDC http://tinyurl.com/jxfm3hb (Abstract Summaries pub. 3-1-17)
...MSKCC+PPHM: 4-2-17/1pm #574, “PSTargeting+RAD+AntiPD1 Promotes Anti-Tumor Activity, Melanoma”
...MSKCC+PPHM: 4-3-17/8am #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Elims. Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=2nd Joint MemSloan/PPHM study, see: http://tinyurl.com/h3ylrku
...PPHM: 4-4-17/8am #3652, “PSTargeting+LAG3+AntiPD1 Significantly Enhances Anti-Tumor Activity, Triple- MBC”
...IMMUNOVACCINE+PPHM: 4-4-17/8am #3657, ”PSTargeting Enhances Anti-Tumor Activity of a Tumor Vaccine(DepoVax), HPV-Induced Tumor”
INTERESTING:
Mem. Sloan’s Dr. Jedd. Wolchok is co-author of 5 AACR’17 Posters. 2 of the 5 are w/PPHM re: PS-Targeting. Only one other is with a biotech: Genocea Biosciences. The 4th is MSKCC ONLY, and the 5th is jointly w/Cedars-Sinai/LA. This is presuming that I searched properly (I think I did): http://www.abstractsonline.com/pp8/#!/4292 .
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine Targeting Antibody in Combination with Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma”
2. 4-3-17 #1651 “Targeting Phosphatidylserine in Combination With Adoptive T Cell Transfer Eliminates Advanced Tumors Without Off-Target Toxicities in a Melanoma Preclin. Model”
NON-PEREGRINE:
3.(MSK ONLY): 4-2-17 #874 “Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy”
4.(MSK & Genocea Bio. http://www.genocea.com GNCA/$130mm MktCap) 4-2-17 #632 “Genome-scale neoantigen screening using ATLAS™ prioritizes candidate antigens for immunotherapy in a NSCLC patient”
5.(MSK & Cedars-Sinai/LA) 34-4-17 #4705 “CTLA4 blockade with HER2-directed therapy yields clinical benefit in women undergoing radiation therapy for HER2+ breast cancer brain metastases”

Apr10-12: Immune Profiling World Congress 2017, WashDC (part of “World Vaccine Congress 2017”) http://tinyurl.com/zlr5cyj
...4-11-17 12:10pm: Dr. Jeff Hutchins***(VP/PreClinRes.), “Increasing the Benefits of Immune Checkpoint Therapies Thru Increased Tumor Infiltrating Activated T-Cells”
***Note: 1-4-17: Dr. Hutchins left Peregrine to become CSO of Heat-Biologics.

??Jun2-6: ASCO 2017, Chicago https://am.asco.org (Abstracts: Titles/MidAPR, Full=May17)

Jun19-22/Avid Booth #1411: BIO Intl. Convention, SanDiego http://www.convention.bio.org/2017

~Jul13: FY'17Q4 (fye 4-30-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm

[biopharm]

**12-12-2012: MSK Researchers Jedd Wolchok & Michel Sadelain Appointed to “Stand Up To Cancer” Immunology “Dream Team”
TWO APPROACHES TO ATTACKING CANCER:
The Immunology Dream Team will pursue 2 research techniques.
The 1st, being led by Dr. Wolchok, involves studying how a type of white blood cell called a T lymphocyte, or T cell, can kill cancer cells. Sometimes, the natural function of the T lymphocyte is blocked or not activated enough to attack cancer cells, allowing the cancer to grow. Part of the Dream Team’s focus will be to investigate ways to ensure that the T lymphocytes work properly in recognizing and killing cancer cells.
The 2nd immunotherapy approach, known as Adoptive Cell Transfer (ACT), involves removing some of a patient’s T cells, enhancing their cancer-fighting abilities and growing them in the laboratory, and then infusing the enhanced cells back into the patient. This can provide a patient with an army of immune cells specifically programmed to fight against cancer. This part of the Dream Team’s research, led by Dr. Sadelain, will investigate several ways to use ACT as a cancer therapy.
https://www.mskcc.org/blog/msk-researchers-appointed-stand-immunology-dream-team

Much more coming from CAR-T / Adoptive Cell Transfer in Feb 2018 and we have Jerome Galon (Immunoscore) and many more...and will list the full lineup in case any changes but first we should be reminded of Jerome Galon

.....
.....
In an effort to promote the Immunoscore in routine clinicalsettings, a worldwide task force was initiated by Dr Galon.

The working group composed of international expert pathologists and immunologists identified a strategy for the organization of a worldwide participation by various groups for the validation of the Immunoscore
..
...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135970680

Emerging Cellular Therapies: T Cells and Beyond (B6)
joint with the meeting on Lymphocytes and their Roles in Cancer (R1)

Scientific Organizers: Carl H. June, Marcela V. Maus and Bruce R. Blazar

February 11—15, 2018
Keystone Resort, Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Editas Medicine, Gilead Sciences, Inc., Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Takeda Pharmaceutical Company Limited

Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at [phone]; [phone] or email [e-mail] if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.

DEADLINES:
Scholarship Deadline: Oct 11, 2017 [details]
Discounted Abstract Deadline: Oct 11, 2017 [details]
Abstract Deadline: Nov 9, 2017 [details]
Discounted Registration Deadline: Dec 13, 2017 [details]

Click here to view Cancellation Policy

Register Yourself Deadlines and Fees


No registration fees are used to fund entertainment or alcohol at this conference

Conference Program Print | View meeting in 12 hr (am/pm) time

The meeting will begin on Sunday, February 11 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 15 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 16 in order to fully experience the meeting.

SUNDAY, FEBRUARY 11

16:00—20:00 Arrival and Registration

Longs Peak Foyer
18:00—20:00 Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Longs Peak Foyer

MONDAY, FEBRUARY 12

07:00—08:00 Breakfast

Colorado Rockies Ballroom
08:00—09:00 Welcome and Keynote Address
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T Cell Recognition in Human Cancer


Following Session is for Lymphocytes and their Roles in Cancer (R1)

08:00—09:00 Welcome and Keynote Address
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Alexander Y. Rudensky, HHMI, Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells and their Functions in the Tumor Microenvironment

09:00—11:15 CAR/TCR Preclinical
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Philip D. Greenberg, University of Washington, USA
Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors

Coffee Break

Crystal L. Mackall, Stanford University, USA
CAR T Cells in Pediatric Malignancies

Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors

Short Talk(s) Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

09:00—11:15 Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Adolfo Ferrando, Columbia University, USA

Louis M. Staudt, NCI, National Institutes of Health, USA
The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas

Coffee Break

Charles G. Mullighan, St. Jude Children's Research Hospital, USA
Biology of Relapse in Acute Lymphoblastic Leukemia

Katia Georgopoulos, Massachusetts General Hospital, USA
Early Events in Lymphocytic Differentiation and Transformation

Anastasia N. Tikhonova†, New York University Medical School, USA
Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment

11:15—17:00 On Own for Lunch

11:15—13:00 Poster Setup

Colorado Rockies Ballroom
13:00—22:00 Poster Viewing

Colorado Rockies Ballroom
14:30—16:30 Workshop 1: Perspectives from Industry and FDA: Roundtable

Grays/Longs Peak
Short Talks Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

14:30—16:30 Workshop 1: Understanding and Targeting Lymphocytes in Cancer

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Eirini Giannakopouou, Radiumhospitalet, Norway
T Cell Receptor-Mediated Targeting Of Recurrent Neoantigens In Acute Myeloid Leukemia

Wenting Zheng, St. Jude Children Research Hospital, USA
PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells

Elena Montauti, Northwestern University, USA
USP22 Maintains Regulatory T cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response

Jeffrey Ward, Washington University School of Medicine, USA
Remodeling of Myeloid as Well as Lymphoid Compartments Following Checkpoint Blockade Immunotherapy

Soki Kashima, Kyoto University, Japan
WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma

Chris Nicolai, University of California, Berkeley, USA
Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists

Julie A. Rytlewski, Adaptive Biotechnologies, USA
History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire

Angela Vasaturo†, INSERM, UMRS1138, France
Unravelling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging

16:30—17:00 Coffee Available

Longs Peak Foyer
17:00—19:00 Synthetic Biology
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Chemically engineering T cell therapies

Wendell A. Lim, University of California, San Francisco, USA
Optimizing Synthetic Biology Tools for T Cell Therapies

Travis Young, California Institute for Biomedical Research, USA
Controllable CAR-T Cell Therapy

Short Talk Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

17:00—19:00 Therapeutic Targeting of Lymphocytic Malignancy
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Charles G. Mullighan, St. Jude Children's Research Hospital, USA

Irene M. Ghobrial, Dana-Farber Cancer Institute, USA
Targeting the Tumor Microenvironment in Multiple Myeloma

Adolfo Ferrando, Columbia University, USA
Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia

Iannis Aifantis, New York University School of Medicine, USA
Targeting Stress Responses in Acute Lymphocytic Leukemia

Jacques G. M. Ghysdael, Institut Curie, France
Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia

19:00—20:00 Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00 Poster Session 1

Colorado Rockies Ballroom

TUESDAY, FEBRUARY 13

07:00—08:00 Breakfast

Colorado Rockies Ballroom

Following Session is for Lymphocytes and their Roles in Cancer (R1)

08:00—11:00 Cellular Therapies in Blood Malignancies and Beyond
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Ugur Sahin, TRON – Translationale Oncology, Germany

Carl H. June, University of Pennsylvania, USA
CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia

Crystal L. Mackall, Stanford University, USA
Recent Updates of Chimeric Antigen Receptor Clinical Trials

Coffee Break

Chiara Bonini, Vita Salute San Raffaele University, Italy
Gene Editing of Memory Stem T Cells for Cancer Immunotherapy

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
Next Generation CAR-T Cell-Expressing Vectors and in vivo Utilization

Charlotte Mousset†, Radboudumc, Netherlands
Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-like T Cells by ex vivo Akt-Inhibition

08:00—11:00 Engineered T Cells for HIV
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Catherine M. Bollard, Children’s National Health System, USA
Developing HIV-specific T Cell Therapies: Lessons from EBV

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Shutting the Door on HIV by Engineering Hematopoietic Stem Cells

Coffee Break

James L. Riley, University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

11:00—17:00 On Own for Lunch

11:00—13:00 Poster Setup

Colorado Rockies Ballroom
13:00—22:00 Poster Viewing

Colorado Rockies Ballroom
16:30—17:00 Coffee Available

Longs Peak Foyer
17:00—19:00 CAR/TCR in the Clinic for Cancer
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Stephen J. Forman, City of Hope, USA
CAR Trials in the Clinic

Marcela V. Maus, Harvard Medical School, USA
CAR T Cells Multiple Myeloma and Glioblastoma

Saar I. Gill, University of Pennsylvania, USA
CAR T Cells for Acute Myelogenous Leukemia

Short Talk Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

17:00—19:00 Lymphocytes as Elements of the Tumor Microenvironment
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Katia Georgopoulos, Massachusetts General Hospital, USA

David H. Raulet, University of California, Berkeley, USA
Immune Surveillance of Cancer Cells by Natural Killer Cells

Michael Kalos, Eli Lilly and Company, USA
T Cells in the Microenvironment: Conductors, First Violin, or Part of the Orchestra?

Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions Between Myeloid and Lymphoid cells Regulate Response to Therapy in Solid Tumors

Annelise Snyder, University of Washington, USA
Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment

19:00—20:00 Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00 Poster Session 2

Colorado Rockies Ballroom

WEDNESDAY, FEBRUARY 14

07:00—08:00 Breakfast

Colorado Rockies Ballroom
08:00—11:00 Tregs as Cellular Therapeutics
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Bruce R. Blazar, University of Minnesota, USA
Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease

Jeffrey A. Bluestone, University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer

Coffee Break

Megan K. Levings, University of British Columbia, Canada
HLA-A2 Directed CAR Tregs

Laurence A. Turka, Massachusetts General Hospital, USA
Alloantigen-specifc Tregs for Solid Organ Transplantation

Short Talk(s) Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

08:00—11:15 Emerging Technologies: Visualization and Dissection of the Tumor Microenvironment
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Mikala Egeblad, Cold Spring Harbor Laboratory, USA

Dana Pe'er, Memorial Sloan Kettering Cancer Center, USA
A Single Cell Approach to Understanding the Tumor Microenvironment

Matthew F. Krummel, University of California, San Francisco, USA
Imaging a World Beyond Checkpoints: Innate Partners for Lymphocytes in Cancer

Coffee Break

Jerome Galon, INSERM U872, Cordeliers Research Center, France
Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer

Michael Goldberg, Dana-Farber Cancer Institute, USA
Enhancing Cancer Immunotherapy through Immuno-engineering

Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics

11:00—17:00 On Own for Lunch

11:00—13:00 Poster Setup

Colorado Rockies Ballroom
13:00—22:00 Poster Viewing

Colorado Rockies Ballroom
14:30—16:30 Workshop 2: Late Breaking Talks

Grays/Longs Peak
Short Talks Chosen from Abstracts

16:30—17:00 Coffee Available

Longs Peak Foyer
17:00—19:00 Beyond T Cells: HSC, T Progenitor, and IPSCs I
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Speaker to be Announced

Martin Pule, University College London, UK
New Designs in Synthetic T Cells

Jeffrey Steven Miller, University of Minnesota, USA
Novel Ways to Activate and Target NK Cells to Treat Cancer

Short Talk Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

17:00—19:00 Emerging Concepts in the Development of Tumor Vaccines
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Dimitris Skokos, Regeneron Pharmaceuticals, USA

Ugur Sahin, TRON – Translationale Oncology, Germany
Systemic RNA Delivery, Dendritic Cell Vaccines and Implications for Cancer Immunotherapy

Cornelis J. M. Melief, Leiden University Medical Center, Netherlands
Combination Immunotherapy of Cancers caused by High Risk HPV16

Johanna Olweus, University of Oslo, Norway
Selecting Immunogenic Targets for Cancer Immunotherapy

Samarth Hegde, Washington University School of Medicine, USA
Short Talk: Tumor Antigenicity Accelerates Early Pancreatic Adenocarcinoma Progression

19:00—20:00 Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
19:30—22:00 Poster Session 3

Colorado Rockies Ballroom

THURSDAY, FEBRUARY 15

07:00—08:00 Breakfast

Colorado Rockies Ballroom
08:00—11:00 Beyond T Cells: HSC, T Progenitor, and IPSCs II
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Juan Carlos Zúñiga-Pflücker, Sunnybrook Research Institute, Canada
Generation of Human Progenitor T Cells from Stem Cells

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA
iPS-Derived Genetically-Modified T Cells

Coffee Break

Jakub Tolar, University of Minnesota, USA
Gene Edited Stem Cells: From Cloning to Clinic

Speaker to be Announced

Short Talk(s) Chosen from Abstracts


Following Session is for Lymphocytes and their Roles in Cancer (R1)

08:00—11:00 Combinatorial Treatments and their Effects on Lymphocyte Function in Cancer
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Ashley M. Laughney, Memorial Sloan Kettering Cancer Center, USA

David G. DeNardo, Washington University Medical School, USA
The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy

Dimitris Skokos, Regeneron Pharmaceuticals, USA
T Cell Dysfunction and Combination Immunotherapy

Coffee Break

Michael A. Curran, University of Texas MD Anderson Cancer Center, USA
Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations

Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
Combination Treatments to Modulate the Microenvironment and Boost Tumor-specific T cells

Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma

11:00—17:00 On Own for Lunch

16:30—17:00 Coffee Available

Longs Peak Foyer
17:00—18:45 Intersection of Genetic Editing and Cellular Therapy
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak
Alex Marson, University of California, San Francisco, USA
Reprogramming Human T Cell Circuitry

Andrew M. Scharenberg, Casebia Therapeutics, USA
Editing T-Cells for Adoptive Therapy of Inflammatory Disorders

Carl H. June, University of Pennsylvania, USA
Adoptive Transfer with Genetically Edited T Cells


Following Session is for Lymphocytes and their Roles in Cancer (R1)

17:00—18:45 Future Directions for Next Generation Sequencing: Genomics, Epigenetics and Immunogenomics
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
* Iannis Aifantis, New York University School of Medicine, USA

Mikala Egeblad, Cold Spring Harbor Laboratory, USA
Visualization of the Switch from Immune Control to Immune Escape

Mickey Atwal, Cold Spring Harbor Laboratory, USA
High Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy

Manel Esteller, Belvitge Biomedical Research Institute (IDIBELL), Spain
Cancer Epigenetics: From Knowlegde to Applications

18:45—19:00 Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 01/11/2018

Grays/Longs Peak

Following Session is for Lymphocytes and their Roles in Cancer (R1)

18:45—19:00 Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 01/11/2018

Quandary Peak
19:00—20:00 Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Colorado Rockies Ballroom
20:00—23:00 Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Colorado Rockies Ballroom

FRIDAY, FEBRUARY 16

Departure


*Session Chair †Invited, not yet responded.


We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors for generously supporting this meeting:
BioLegend, Inc. Editas Medicine
Gilead Sciences, Inc. Juno Therapeutics
Regeneron Pharmaceuticals, Inc. Sangamo Therapeutics, Inc.
Takeda Pharmaceutical Company Limited

https://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1518

[biopharm]

DREAM TEAM LEADERSHIP: 10 scientists, incl. MSKCC’s Jedd D. Wolchok & Michel Sadelain.
http://parker.org/initiatives/immunotherapy
-----
**12-12-2012: MSK Researchers Jedd Wolchok & Michel Sadelain Appointed to “Stand Up To Cancer” Immunology “Dream Team”
TWO APPROACHES TO ATTACKING CANCER:
The Immunology Dream Team will pursue 2 research techniques.
The 1st, being led by Dr. Wolchok, involves studying how a type of white blood cell called a T lymphocyte, or T cell, can kill cancer cells. Sometimes, the natural function of the T lymphocyte is blocked or not activated enough to attack cancer cells, allowing the cancer to grow. Part of the Dream Team’s focus will be to investigate ways to ensure that the T lymphocytes work properly in recognizing and killing cancer cells.
The 2nd immunotherapy approach, known as Adoptive Cell Transfer (ACT), involves removing some of a patient’s T cells, enhancing their cancer-fighting abilities and growing them in the laboratory, and then infusing the enhanced cells back into the patient. This can provide a patient with an army of immune cells specifically programmed to fight against cancer. This part of the Dream Team’s research, led by Dr. Sadelain, will investigate several ways to use ACT as a cancer therapy.
https://www.mskcc.org/blog/msk-researchers-appointed-stand-immunology-dream-team

= = = = = = = = = = = = =THE 1st KNOWN PPHM+MSK STUDY:
AACR’17(4-2-17 http://tinyurl.com/jxfm3hb ), same as SITC’16(Nov2016)
SITC’16: “Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade & Tumor Radiation Therapy Promotes Anti-Cancer Activity in Mouse Melanoma”
AACR’17: “Phosphatidylserine Targeting Antibody in Combination with Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma”
AACR’17 AUTHORS: Sadna Budhu, Olivier De Henau, Roberta Zappasodi, Rachel Giese, Luis F. Campesato, Christopher Barker, Bruce Freimark, Jeff Hutchins, Jedd D. Wolchok, Taha Merghoub (same list as SITC’16, except K.Schlunegger dropped/now at Pfenex, and MSKCC’s L.Campesato & R.Geise added)
...From the SITC’16 abstract: http://tinyurl.com/js3fca4
“We found that the PS-targeting antibody synergizes with both anti-PD-1 and radiation therapy to improve anti-cancer activity and overall survival. In addition, the triple combination of the PS-targeting antibody, tumor radiation and anti-PD-1 treatment displayed even greater anti-cancer & survival benefit. This finding highlights the potential of combining these 3 agents to improve outcome in patients with advanced-stage melanoma and may inform the design of future clinical trials with PS targeting in melanoma and other cancers.”
...From PPHM’s 11-14-16 SITC’16 PR: http://tinyurl.com/js3fca4
DR. JEDD WOLCHOK: "Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact."
DR. TAHA MERGHOUB (Co-Dir., Ludwig Collaborative Lab at MSK): "We have noted that the combination of PS-targeting treatment and radiation, as well as triple combination of PS-targeting treatment, radiation and anti-PD-1, resulted in clear advantages in anti-tumor activity in the mouse B16 melanoma model. We believe that these findings suggest the potential benefit of combining these agents to improve the outcomes of patients with cancer. With this in mind, we think this research may play an important role in designing future clinical trials of PS-targeting agents in melanoma and other cancers."

= = = = =THE OTHER 2 (of 4 total) AACR’17 PPHM ABSTRACTS:
4-4-17/8am #3652 - Session: BITES BISPECIFICS & CHECKPOINTS
“Combinational Activity of LAG3 & PD-1 Targeted Therapies is Significantly Enhanced by the Addition of Phosphatidylserine Targeting Antibodies and Establishes an Anti-Tumor Memory Response in Murine Triple Negative Breast Cancer”
=> Michael J. Gray, Jian Gong, Jeff Hutchins, Bruce Freimark (Peregrine Pharmaceuticals)

4-4-17/8am #3657 - Session: BITES BISPECIFICS & CHECKPOINTS
”Phosphatidylserine-Targeting Antibodies Enhance Anti-Tumor Activity of a Tumor Vaccine in a HPV-Induced Tumor Model”
=> Genevieve Weir 1, Tara Quinton 1, Jeff T. Hutchins 2, Bruce D. Freimark 2, Marianne Stanford (VP/Res., Immunovaccine)
1=Immunovaccine, Inc., Halifax, NS, Canada [ https://www.imvaccine.com ]
2=Peregrine Pharmaceuticals
[Note: clearly, this study is combining PPHM’s Anti-PS with ImmunoVaccine’s DepoVax Vaccine Adjuvanting Platform https://www.imvaccine.com/depovax.php ]
.
.
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
...The studies at MSK will be performed under the direction of Taha Merghoub, PhD, [ http://www.mskcc.org/research-areas/labs/members/taha-merghoub-01 ] Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, MD, PhD [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ], a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation as well as an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.
----
”The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Jedd Wolchok.
....
..

I wonder what new knowledge was gained out of Memorial Sloan Kettering scientists related to PS Targeting patents, that was impossible to have been discovered if it were not for the collaborations with Peregrine Pharmaceuticals and now, the new BODs have somehow agreed on a deal with much royalties coming from Oncologie....

Would be nice if Michel Sadelain went public with his knowledge gained from PS Targeting collaborations and now the hours count down before a CDMO contract continue to roll in